Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
Theravance Biopharma (NASDAQ: TBPH) has scheduled its second quarter 2025 financial results announcement and business update for August 12, 2025, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Theravance Biopharma (NASDAQ: TBPH) has scheduled its second quarter 2025 financial results announcement and business update for August 12, 2025, after market close. The company will host a conference call and webcast at 5:00 pm ET on the same day.
Interested participants can pre-register for the telephone conference, while those preferring to listen via the internet can access the webcast through the company's website. A replay will be available for 30 days through September 11, 2025.
Details
News Market Reaction – TBPH
The recorded move for TBPH in the trading session of this news was +0.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Information
To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by clicking here or visiting the Events and Presentation page under the Investors Section on Theravance Biopharma's website.
A replay of the webcast will be available on Theravance Biopharma's website for 30 days through September 11, 2025.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-second-quarter-2025-financial-results-on-august-12-2025-302514625.html
SOURCE Theravance Biopharma, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.